While patients with LM were excluded from this study, these encouraging results prompted the development of a phase II trial of combination tucatinib, trastuzumab, and capecitabine in patients with HER2+ breast cancer and LM (NCT03501979) [110]. Here, ERBB2 is linked to breast cancer.